

Express Mail No.: EV869874291US  
Date of Deposit: January 3, 2008



Page 1 of 2  
Attorney Docket No.: 23239-544

Please type a plus sign (+) in this box



PTO/SB (12-97)  
Approved for use through 9/30/00. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>Modified Form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Application Number</b>		10/729,581	
				<b>Filing Date</b>		December 3, 2003	
				<b>First Named Inventor</b>		Keefe	
				<b>Group Art Unit</b>		1637	
				<b>Examiner Name</b>		Mark Staples	
				<b>Attorney Docket Number</b>		23239-544	
<b>U.S. PATENT DOCUMENTS</b>							
<b>Exam Initials</b>	<b>Cite No.</b>	<b>U.S. Patent Document No.</b>	<b>Issue Date</b>	<b>Name of Patentee(s) or Applicant(s)</b>	<b>Class</b>	<b>Sub Class</b>	<b>Filing Date If Appropriate</b>
<b>U.S. PUBLISHED APPLICATION DOCUMENTS</b>							
<b>Exam Initials</b>	<b>Cite No.</b>	<b>U.S. Published Application No.</b>	<b>Published Date</b>	<b>Name of Patentee(s) or Applicant(s)</b>	<b>Class</b>	<b>Sub Class</b>	<b>Filing Date If Appropriate</b>
<b>FOREIGN PATENT DOCUMENTS</b>							
<b>Exam Initials</b>	<b>Cite No.</b>	<b>Foreign Patent Document Office Number</b>		<b>Name of Patentee(s) or Applicant(s)</b>	<b>Date of Publication</b>	<b>Translation Yes No</b>	
	B20	WO	95/07364	NEXAGEN, INC.	03/16/95		
<b>OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS</b>							
<b>Exam Initials</b>	<b>Cite No.</b>	<b>Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.</b>					
	C109	Bridonneau et al., "Purification of highly modified RNA-aptamer Effect of complete denaturation during chromatography on product recovery and specific activity", <i>J. Chromatography B</i> 726(1-2):237-247 (1999)					
	C110	Burmeister et al., "Direct In Vitro Selection of a 2'-O-Methyl Aptamer to VEGF", <i>Chem. Biol.</i> 12(1):25-33 (2005)					
	C111	Burmeister et al., "2'-Deoxy Purine, 2'-O-Methyl Pyrimidine (dRmY) Aptamers as Candidate Therapeutics", <i>Oligonucleotides</i> 16(4):337-351 (2006)					
	C112	Chelliserrykattil et al., "Evolution of a T7 RNA polymerase variant that transcribes 2'-O-methyl RNA", <i>Nat. Biotechnol.</i> 22(9):1155-1160 (2004)					
	C113	Fa et al., "Expanding the Substrate Repertoire of a DNA Polymerase by Directed Evolution", <i>J. Am. Chem. Soc.</i> 126(6):1748-1754 (2004)					
	C114	Gudima et al., "Synthesis of mixed ribo/deoxyribopolynucleotides by mutant T7 RNA polymerase", <i>FEBS Lett.</i> 439(3):302-306 (1998)					

	C115	Kostyuk et al., "Mutants of T7 RNA polymerase that are able to synthesize both RNA and DNA", <i>FEBS Lett.</i> 369(2-3):165-168 (1995)
	C116	Majlessi et al., "Advantages of 2'-O-methyl oligoribonucleotide probes for detecting RNA targets", <i>Nuc. Acids Res.</i> 26(9):2224-2229 (1998)
	C117	Ruckman et al., "2'-Fluoropyrimidine RNA-Based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF <sub>165</sub> )", <i>J. Biol. Chem.</i> 273(32):20556-20567 (1998)
	C118	Uhlmann et al., "15 Use of Minimally Modified Antisense Oligonucleotides for Specific Inhibition of Gene Expression", <i>Meth. Enzymol.</i> 313:268-284 (2000)
	C119	Supplementary European Search Report for EP 03 81 2519

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.